Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
Open accessAbstract
Background: Alzheimer's disease co‐pathology is common in dementia with Lewy bodies and Parkinson's disease with dementia (Lewy body disease) and can reliably be detected with positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers. Recently developed blood biomarkers are more accessible and less expensive alternatives. Objective: To investigate if plasma phospho‐tau217 and phospho‐tau181 can detect Alzheimer's pathology in Lewy body disease with dementia. Methods: In this cross‐sectional study we investigated plasma phospho‐tau217 and phospho‐tau181 in 35 patients with Lewy body disease with dementia. Patients underwent tau‐PET imaging ( 18 F‐RO948). Results: Plasma phospho‐tau217 correlated with plasma phospho‐tau181, CSF phospho‐tau217 (r s = 0.68, P < 0.001), and negatively with CSF β‐amyloid 42/40 (r s = −0.52, P = 0.001). Plasma phospho‐tau217 and phospho‐tau181 correlated with tau‐PET signal in the temporal cortex (r s > 0.56, P < 0.001) and predicted abnormal tau‐PET status and β‐amyloid status (area under the curve > 0.78 and > 0.81, respectively). Conclusion: Plasma phospho‐tau might be a useful marker for Alzheimer's co‐pathology in Lewy body disease with dementia. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plasma tau has emerged as a marker of neuronal distress and appears in several neurodegenerative diseases, including preclinical AD.
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · see citing works
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247 · see citing works
Self-citationParkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 875 · see citing works
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761 · see citing works
Self-citationIrwin, D. J., Grossman, M., Weintraub, D. A., Hurtig, H. I., Duda, J. E., Xie, S. X., Lee, E. B., Deerlin, V. M. V., López, O. L., Kofler, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30291-5 · Cited by 588 · see citing works
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499 · see citing works
Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472 · see citing works
Self-citationAmyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works
Self-citationCerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450 · see citing works
Self-citationEdison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N. M., Villemagne, V. L., O'Keefe, G. J., Någren, K., Chaudhuri, К. R., et al. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127878 · Cited by 422 · see citing works
Cortical Lewy body pathology in the diagnosis of dementia
Harding, A. J., & Halliday, G. M. (2001) · Acta Neuropathologica · doi:10.1007/s004010100390 · Cited by 296 · see citing works
Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273 · see citing works
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 265 · see citing works
Kövari, E., Gold, G., Herrmann, F. R., Canuto, A., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0705-2 · Cited by 229 · see citing works
Barthélemy, N. R., Bateman, R. J., Hirtz, C., Marin, P., Becher, F., Sato, C., Gabelle, A., & Lehmann, S. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00596-4 · Cited by 229 · see citing works
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Gomperts, S. N., Locascio, J. J., Makaretz, S. J., Schultz, A. P., Caso, C., Vasdev, N., Sperling, R. A., Growdon, J. H., Dickerson, B. C., & Johnson, K. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3338 · Cited by 228 · see citing works
Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0989 · Cited by 222 · see citing works
Self-citationSmith, C., Malek, N., Grosset, K. A., Cullen, B., Gentleman, S., & Grosset, D. G. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321111 · Cited by 201 · see citing works
Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution
Ferman, T. J., Aoki, N., Boeve, B. F., Aakre, J. A., Kantarci, K., Graff‐Radford, J., Parisi, J. E., van Gerpen, J. A., Graff‐Radford, N. R., Uitti, R. J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009763 · Cited by 100 · see citing works
Ruffmann, C., Calboli, F. C. F., Bravi, I., Gveric, D. O., Curry, L. K., de Smith, A. J., Pavlou, S., Buxton, J. L., Blakemore, A. I. F., Takousis, P., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12294 · Cited by 96 · see citing works
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
Smith, R., Schöll, M., Leuzy, A., Jögi, J., Ohlsson, T., Strandberg, O., & Hansson, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04496-0 · Cited by 88 · see citing works
Self-citationDementia with Lewy bodies — from scientific knowledge to clinical insights
Arnaoutoglou, N. A., O'Brien, J. T., & Underwood, B. R. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0107-7 · Cited by 87 · see citing works
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Smith, R. A., Schöll, M., Londos, E., Ohlsson, T. G., & Hansson, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-23041-x · Cited by 75 · see citing works
Self-citationParkinson's and Lewy body dementia CSF biomarkers
Parnetti, L., Paciotti, S., Farotti, L., Bellomo, G., Sepe, F. N., & Eusebi, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.078 · Cited by 54 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hyman, B. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-023749 · Cited by 39 · see citing works
- Authors
- Hall, S., Janelidze, S., Londos, E., Leuzy, A., Stomrud, E., Dage, J. L., & Hansson, O.
- Affiliations
- Lund University (SE)
- Eli Lilly (United States) (US)
- Corresponding author
- Hall, Sara
- Hansson, Oskar
- ORCID
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2020-12-07
- Volume
- 36
- Issue
- 3
- Pages
- 767-771
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- PMC
- PMC8048822
- OpenAlex
- W3111319985
- Cited by
- 80
- References
- 26
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 12 · 2022: 17 · 2021: 5
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Movement Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Funders
- Alzheimerfonden
- Knut och Alice Wallenbergs Stiftelse
- Marianne and Marcus Wallenberg Foundation
- Parkinsonfonden
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease co-pathology, Lewy body disease, dementia with Lewy bodies, Parkinson's disease dementia, blood biomarkers, tau PET imaging, cerebrospinal fluid biomarkers, temporal cortex
- MeSH terms
- Alzheimer Disease, Cross-Sectional Studies, Humans, Plasma, Biomarkers, Amyloid beta-Peptides, tau Proteins, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
